Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 12/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 12/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 11/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5298388 | 1.00 | SLC7A5 (0.48) | SLC7A5SLC1A3SLC1A2SLC1A1USP2 | |
| SCHEMBL865283 | 0.82 | SLC7A5 (0.43) | SLC7A5SLC1A3SLC1A2SLC1A1USP2 | |
| SCHEMBL9183338 | 0.82 | SLC7A5 (0.43) | SLC7A5SLC1A3SLC1A2SLC1A1USP2 | |
| SCHEMBL865284 | 0.82 | SLC7A5 (0.43) | SLC7A5SLC1A3SLC1A2SLC1A1USP2 | |
| SCHEMBL757841 | 0.78 | — | — | |
| SCHEMBL3798816 | 0.78 | — | — | |
| SCHEMBL1007447 | 0.75 | SLC7A5 (0.62) | SLC7A5SLC1A3SLC1A2SLC1A1USP2 | |
| SCHEMBL29957453 | 0.75 | SLC7A5 (0.62) | SLC7A5SLC1A3SLC1A2SLC1A1USP2 | |
| SCHEMBL468084 | 0.75 | SLC7A5 (0.62) | SLC7A5SLC1A3SLC1A2SLC1A1USP2 | |
| SCHEMBL600021 | 0.75 | SLC7A5 (0.62) | SLC7A5SLC1A3SLC1A2SLC1A1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240325517-A1 | COMPOSITIONS AND METHODS TARGETING FILAMENTOUS BACTERIOPHAGE | INIMMUNE CORPORATION | 2024-10-03 | — | — | US | disclosed |
| CN-117623959-A | Synthesis method of threo-3-fluoro-N-9-phenyl-9-fluorene-L-tert-butyl aspartate | 吉尔多肽生物制药(大连市)有限公司 | 2024-03-01 | — | — | CN | disclosed |
| EP-4213943-A1 | COMPOSITIONS AND METHODS TARGETING FILAMENTOUS BACTERIOPHAGE | The University Of Montana (US) | 2023-07-26 | — | — | EP | disclosed |
| WO-2022060905-A1 | COMPOSITIONS AND METHODS TARGETING FILAMENTOUS BACTERIOPHAGE | THE UNIVERSITY OF MONTANA (US) | 2022-03-24 | — | — | WO | disclosed |
| US-8445440-B2 | Dimeric IAP inhibitors | NOVARTIS AG (CH) | 2013-05-21 | — | — | US | disclosed |
| EP-2539333-A1 | DIMERIC IAP INHIBITORS | Novartis AG (CH) | 2013-01-02 | — | — | EP | disclosed |
| WO-2011104266-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2011-09-01 | — | — | WO | disclosed |
| US-20110206690-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240325517-A1 | COMPOSITIONS AND METHODS TARGETING FILAMENTOUS BACTERIOPHAGE | TLR8, TLR3, TLR4 | SLC7A5 3298/4885SLC1A3 4056/4885SLC1A2 4497/4885 |
| US-20110206690-A1 | DIMERIC IAP INHIBITORS | XIAP, BIRC5, BIRC2 | SLC7A5 3081/4885SLC1A3 4126/4885SLC1A2 4283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.